Oct 31, 2017

The Scientific Advisory Board will oversee the development of GB Sciences’ Cannabis-Based Therapies and Clinical Trials


LAS VEGAS, November 1, 2017/PR Newswire/--GB Sciences, Inc. (OTCQB: GBLX) inducts a Scientific Advisory Board to provide oversight for product development within GB Sciences’ intellectual property portfolio, consisting of three original patent applications, one licensed patent application, and one licensed approved patent. GB Sciences remains committed to discovering novel cannabis-based therapies for disease-specific applications; as well as producing standardized patent-pending formulations and ensuring their efficacy through well-controlled clinical trials. The Scientific Advisory Board will be tasked with efficiently managing GB Sciences’ resources while creating and testing their proprietary cannabis-based formulas.

The Scientific Advisory Board will be chaired by Dr. Andrea Small Howard, Chief Science Officer of GB Sciences, Inc. “We are very honored to welcome some new members to our Scientific Advisory Board this year; as well as, Dr. Helen Turner, who has worked with GB Sciences for the past four years. Dr. Turner, VP of Innovation, Dean of Natural Sciences and Mathematics at Chaminade University, has been my collaborator on the discovery of our novel cannabis-based therapies since the beginning, and she is a co-inventor with me on all of GB Sciences’ original patent applications,” said Dr. Small-Howard. “Joining the team this year are Dr. Norbert Kaminski of Michigan State University, whose laboratory was the first to discover cannabinoid receptor expression in the immune system, who pioneered studies of the effects of cannabis on immune modulation, and who has more recently been studying the effects of cannabis use on patients with HIV/AIDS. Dr. Carlos F. Ríos-Bedoya from McLaren Health, has been a pioneer in the use of mobile technology and Patient Reported Outcome software to expedite data gathering in clinical trials. In addition, Dr. Ríos-Bedoya brings experience in clinical trial protocol development and statistics to our team.” Full biographies for our Scientific Advisory Board members are available on our website.

“GB Sciences is committed to putting safe and effective cannabis-based medicines into the hands of the patients who need it, and doing it as quickly as possible,” said John Poss, CEO and Chairman of GB Sciences, Inc.  “We believe that our Scientific Advisory Board has the skills and connections to make this happen.”


Dr. Andrea Small-Howard, Chief Science Officer, GB Sciences, LLC

Andrea Small

Dr. Andrea Small-Howard leverages broad biopharmaceutical industry knowledge and contacts in her current dual roles as the Chief Science Officer and member of the Board of Directors at GB Sciences, Inc.  She brings to GB Sciences a passion for advancing clinical research on medicinal applications of cannabinoid compounds in cannabis plants, clinical experience in conducting cannabinoid research, strategic vision for creating a vertically integrated biopharmaceutical pipeline, and a track record of successes in the management of biopharmaceutical companies. 

Dr. Small-Howard has more than 15 years’ experience studying cannabinoids and the endocannabinoid system, immunology and cancer treatments; as well as executive experience in the biopharmaceutical industry where she supervised research and development, manufacturing and quality control divisions. She took the lead in obtaining regulatory approvals from the U.S. Food and Drug Administration ("US FDA") and multiple international regulatory agencies, and has assisted state jurisdictions in developing medical cannabis regulations.

Dr. Small-Howard originally received her AB from Occidental College (Magna Cum Laude, Phi Beta Kappa), in addition to receiving both an MBA (Beta Gamma Sigma) and a PhD (USC All-University Merit Fellow) in biological sciences from the University of Southern California.  As a post-doctoral fellow at the Queens Medical Center in Honolulu, Hawaii, Dr. Small-Howard led a project group dedicated to the study of cannabinoids in the immune system and published two peer-reviewed papers on the subject.  At the John A. Bums School of Medicine – University of Hawaii, she led a productive research team as a Research Assistant Professor. 

Dr. Small-Howard has held management positions at AMDL, Inc. (a small public biotech company), where she took the lead in every stage of product development from discovery through commercialization.  As Vice President of Scientific Oversight at Radient Pharmaceuticals Corp. (RPC), she provided strategic technical and regulatory oversight for global product development in multiple international business divisions.  At RPC, she also played an active role in creating collaboration agreements with development partners and research institutions, and she contributed to critical licensing and distribution agreements. 

For a four year term, she served on the Board of Directors for the Center for Healthcare Innovation, a nonprofit, non-partisan, and independent organization based in Chicago that is committed to serving as a catalyst for stimulating ideas, people, companies, and institutions to collaborate and achieve excellence in healthcare innovation.

Dr. Helen Turner, VP Innovation, Dean of Natural Sciences & Mathematics, Chaminade University

Helen Small

Helen Turner is Vice President of Innovation and Dean of the Division of Natural Sciences and Mathematics at Chaminade University in Honolulu, Hawaii. She is a tenured Professor of Biology at Chaminade, and holds an affiliate Professorship at the University of Hawaii School of Medicine.  

Dr. Turner moved to the U.S. in 1998 from her native England. After completing her Ph.D. at the University of London she carried out post-doctoral work at Harvard medical School as a Wellcome Trust International Prize Travelling Fellow. In 2000, she accepted a position as Associate Director of Research and Professor at The Queen’s Center for Biomedical Research in Honolulu. Here, she built a successful and internationally recognized research laboratory, receiving her first NIH RO1 grant at the age of 30. Her research interests focus upon information transmission in the immune system, specifically on the molecular mechanisms that activate the pro-inflammatory mast cells. She has trained numerous graduate students and post-doctoral fellows for successful careers in academia, industry and science policy. She is a sought-after reviewer of Federal and Foundation grants, and sits on a number of executive boards for research and training initiatives in the sciences.

Since joining Chaminade in 2007, Dr. Turner has fostered transformational growth in the sciences.  As a Federally-designated Native Hawaiian serving institution, Chaminade is positioned to lead in undergraduate science education, serving students and community in Hawaii and the Pacific. She has led the $14m renovation of instructional and research laboratories, raised $20m in funding for the initiation of a BSN program, and secured Chaminade’s first major research and programmatic funding from agencies such as NIH, NSF and the Department of Defence. New faculty hires and major instrumentation grants have invigorated the undergraduate experience in sciences, and complete curriculum revision in computational sciences and the biological sciences has been completed. Curriculum and faculty research interests now align around the mechanisms and epidemiology of diseases that disproportionately affect the peoples of the Pacific, allowing the University to envision itself as a center of excellence for training and education in this field.

Dr. Norbert E. Kaminski, Professor, Department of Pharmacology & Toxicology, MSU

Norbert Small

Dr. Norbert E. Kaminski is a Professor in the Department of Pharmacology and Toxicology and is the Director of the Institute for Integrative Toxicology, at Michigan State University. Dr. Kaminski’s laboratory has been investigating the molecular mechanisms by which cannabinoids alter immune competence for over 22 years, which began with his laboratory’s discovery of cannabinoid receptor expression within cells of the immune system.

Dr. Kaminski has over 28 years of experience in conducting hypothesis driven investigative research directed at elucidation of the cellular and molecular mechanisms by which drugs and chemicals alter immune competence. These immunopharmacological and immunotoxicological studies have utilized approaches spanning measurements of immune function in vivo, ex vivo and in vitro employing rodent and human primary leukocytes and cell lines. Dr. Kaminski’s laboratory has also had a longstanding focus on elucidation of the molecular mechanisms that are responsible for impairment of B cell function by dioxins. He is the author of over 135 journal articles 25 Book Chapters and Reviews and 245 Abstracts.

Dr. Kaminski joined the Michigan State faculty in 1993.  He was also affiliated with the Medical College of Virginia in their Department of Pharmacology and Toxicology from 1985-1999.  He received his B.A. in Chemistry in 1978 from Loyola University in Chicago, Illinois, and his M.S. in Toxicology in 1981 and Ph.D. in Toxicology and Physiology in 1985 from North Carolina State University in Raleigh, North Carolina.

Dr. Kaminski has served on a number of advisory panels including National Academy of Science/IOM Review of the Health Effects in Vietnam Veterans of Exposure to Herbicides, 1992-1994; US EPA Science Advisor Board-Dioxin Reassessment Review, 1995; National Academy of Sciences IOM Study on the Assessment of the Health Implications of Exposure to Dioxins, National Academy of Sciences Study on the Health Effects of Cannabis and Cannabinoids, and is presently on the National Academy of Sciences Committee  Committee on Emerging Science on Environmental Health.  Dr. Kaminski was a member of the Board of Trustees: International Life Sciences Institute-Health and Environmental Sciences Institute 2003-2012.

Dr. Kaminski has also served on a number of peer review panels including US EPA Science Review Panel for Health Research, 1990-92 and NIH ALTX-4 Study Section as a regular member from 1998-03; as an ad hoc member for NIDA, NIEHS, NIOSH, and Wellcome Trust.  Dr. Kaminski served as a member of the National Advisory Environmental Health Sciences Council, Division of Extramural Research and Training for NIEHS.  Dr. Kaminski served as Treasurer for the Society of Toxicology from 2005-2007.  Dr. Kaminski served as the President for the Society of Toxicology from 2014-2015. 

Dr. Carlos F. Rios-Bedoya, Corporate Director of Scholarly Inquiry, McLaren Health

Carlos Small

Dr. Carlos F. Rios-Bedoya is the Corporate Director of Scholarly Inquiry at McLaren Health overseeing research across 13 health care facilities with over 30 residency programs in Michigan.  

Dr. Ríos-Bedoya has been a principal investigator and co-investigator in several highly competitive federal (CDC), state (Michigan Department of Community Health), and private (Pfizer, Gilead, and Boehringer-Ingelheim) funded grants in the areas of HCV, drug use epidemiology, clinical trials, mental health, and mobile technology. Dr. Rios-Bedoya has an extensive publication record in peer-reviewed journals on the field of legal and illegal drug use on topics such as HCV/HIV, statistical methods, use of mobile technology, and differences across Hispanic groups.  

Dr. Carlos F. Ríos-Bedoya graduated in 1986 from the University of Puerto Rico, Río Piedras Campus, with a Bachelor of Science (B.S.) degree majoring in biology. In 1987, he finished a Master in Public Health (M.P.H.) with a concentration in epidemiology also from the University of Puerto, Medical Sciences Campus, and in 1999 he completed his doctoral training (Sc.D.) in Psychiatric Epidemiology with a minor in biostatistics from The Johns Hopkins University’s Bloomberg School of Public Health. He did a three-year post-doctoral training (2004-2007) as a National Institute on Drug Abuse (NIDA) fellow on the quantitative aspects of drug dependence epidemiology from The Johns Hopkins University’s Bloomberg School of Public Health. He has been a faculty member of the Ponce School of Medicine (1994-2004), the San Juan Bautista School of Medicine (2012-2014), and the College of Human Medicine at Michigan State University (2007-2015).  

Dr. Ríos-Bedoya has been invited to present his research at national and international meetings. He currently serves as grant reviewer for the Florida Department of Health’s Multi-Disciplinary, Multi-Institutional and Community-Based (MMC) Grants Program and for the Substance Abuse and Mental Health Services Administration (SAMHA). He is also a reviewer for several of the most prestigious peer-reviewed journals in drug use research (e.g., Nicotine and Tobacco Research, Addiction, Drug and Alcohol Dependence, Psychology of Addictive Behaviors, Addiction Medicine, and American Journal of Preventive Medicine).

About GB Sciences, Inc.

GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control.  It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov.  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Note:  Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.

Contact Information

Corporate:

GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118

866-721-0297, or 

Tom Arcuragi, SR VP Marketing, tom@gbsciences.com, http://gbsciences.com